BRPI0507604A - medicamentos com atividade de receptor hm74a - Google Patents

medicamentos com atividade de receptor hm74a

Info

Publication number
BRPI0507604A
BRPI0507604A BRPI0507604-8A BRPI0507604A BRPI0507604A BR PI0507604 A BRPI0507604 A BR PI0507604A BR PI0507604 A BRPI0507604 A BR PI0507604A BR PI0507604 A BRPI0507604 A BR PI0507604A
Authority
BR
Brazil
Prior art keywords
alkyl
hm74a
medicines
hydrogen
receptor activity
Prior art date
Application number
BRPI0507604-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Ivan Leo Pinto
Shahzad Sharooq Rahman
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BRPI0507604A publication Critical patent/BRPI0507604A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0507604-8A 2004-02-14 2005-02-10 medicamentos com atividade de receptor hm74a BRPI0507604A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Publications (1)

Publication Number Publication Date
BRPI0507604A true BRPI0507604A (pt) 2007-07-03

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507604-8A BRPI0507604A (pt) 2004-02-14 2005-02-10 medicamentos com atividade de receptor hm74a

Country Status (25)

Country Link
US (5) US7713982B2 (enExample)
EP (1) EP1781657B1 (enExample)
JP (2) JP5001012B2 (enExample)
KR (1) KR101100601B1 (enExample)
CN (2) CN101863888B (enExample)
AR (1) AR047669A1 (enExample)
AU (1) AU2005212816C1 (enExample)
BR (1) BRPI0507604A (enExample)
CA (1) CA2556073C (enExample)
CY (1) CY1114022T1 (enExample)
DK (1) DK1781657T3 (enExample)
ES (1) ES2406732T3 (enExample)
HR (1) HRP20130406T1 (enExample)
IL (1) IL177051A (enExample)
MA (1) MA28357A1 (enExample)
MY (1) MY148937A (enExample)
NO (1) NO337281B1 (enExample)
NZ (1) NZ548496A (enExample)
PE (1) PE20060317A1 (enExample)
PL (1) PL1781657T3 (enExample)
PT (1) PT1781657E (enExample)
SG (1) SG157242A1 (enExample)
SI (1) SI1781657T1 (enExample)
TW (1) TWI350289B (enExample)
WO (1) WO2005077950A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL206890B1 (pl) * 1999-11-12 2010-10-29 Biogen Idec Ma Pochodna bicykloalkilopuryny, jej zastosowanie i kompozycja leku
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
SI1781657T1 (sl) * 2004-02-14 2013-07-31 Glaxosmithkline Intellectual Property Development Limited Zdravila z aktivnostjo na receptor hm74a
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
AU2006247695B2 (en) 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006259137B2 (en) * 2005-06-14 2010-04-01 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
HRP20110295T1 (hr) 2005-06-28 2011-05-31 Merck Sharp & Dohme Corp. Agonisti receptora niacina, smjese koje sadržavaju takve spojeve i postupci liječenja
EP1912992A1 (en) * 2005-08-10 2008-04-23 SmithKline Beecham Corporation Xanthine derivatives as selective hm74a agonists
CN101400682A (zh) * 2006-01-20 2009-04-01 先灵公司 治疗异常脂血症的杂环烟酸受体激动剂
MX2008014689A (es) * 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
CA2656039A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
AR061626A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
CA2680775A1 (en) 2007-03-23 2008-10-02 F. Hoffmann-La Roche Ag Aza-pyridopyrimidinone derivatives
PL2370440T3 (pl) * 2008-12-08 2015-05-29 Glaxosmithkline Llc Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
BR112017016065A2 (pt) * 2015-01-30 2018-04-03 Shanton Pharma Co., Ltd. prevenção ou tratamento de ácido úrico ou doença gotosa
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
MX2019008230A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
JP2022549807A (ja) * 2019-09-25 2022-11-29 ゴールドフィンチ バイオ，インク． キサンチンｃｂ１阻害物質
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
AU2024229006A1 (en) * 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
ATE230990T1 (de) 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
EP0746557A4 (en) * 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
JP2002541258A (ja) 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
KR100502757B1 (ko) * 1999-08-31 2005-07-22 반더빌트유니버시티 Ａ２ｂ 아데노신 수용체의 선택적인 길항제
EP1305328A2 (en) * 2000-07-21 2003-05-02 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
JP2004512278A (ja) * 2000-09-19 2004-04-22 ノビムーヌ　ソシエテ　アノニム 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤）
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
HU230384B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
US20040254224A1 (en) * 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
SI1781657T1 (sl) 2004-02-14 2013-07-31 Glaxosmithkline Intellectual Property Development Limited Zdravila z aktivnostjo na receptor hm74a
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
EP1912992A1 (en) 2005-08-10 2008-04-23 SmithKline Beecham Corporation Xanthine derivatives as selective hm74a agonists
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
PL2370440T3 (pl) * 2008-12-08 2015-05-29 Glaxosmithkline Llc Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
PL1781657T3 (pl) 2013-08-30
WO2005077950A3 (en) 2007-04-19
CY1114022T1 (el) 2016-07-27
CN101863888B (zh) 2012-07-18
NZ548496A (en) 2010-02-26
US8394808B2 (en) 2013-03-12
IL177051A (en) 2013-01-31
TW200536537A (en) 2005-11-16
WO2005077950A2 (en) 2005-08-25
CN101103030A (zh) 2008-01-09
AU2005212816C1 (en) 2010-03-04
CN101863888A (zh) 2010-10-20
SG157242A1 (en) 2009-12-29
ES2406732T3 (es) 2013-06-07
IL177051A0 (en) 2006-12-10
MY148937A (en) 2013-06-14
US20100160354A1 (en) 2010-06-24
JP5020848B2 (ja) 2012-09-05
NO20064151L (no) 2006-11-06
CN101103030B (zh) 2010-10-13
AU2005212816B2 (en) 2009-07-23
JP2008120831A (ja) 2008-05-29
US7713982B2 (en) 2010-05-11
PT1781657E (pt) 2013-05-23
CA2556073C (en) 2012-01-10
PE20060317A1 (es) 2006-06-22
CA2556073A1 (en) 2005-08-25
HK1104530A1 (en) 2008-01-18
AU2005212816A1 (en) 2005-08-25
TWI350289B (en) 2011-10-11
DK1781657T3 (da) 2013-06-10
JP2007522176A (ja) 2007-08-09
NO337281B1 (no) 2016-02-29
US20070135456A1 (en) 2007-06-14
US8268839B2 (en) 2012-09-18
KR20060126772A (ko) 2006-12-08
JP5001012B2 (ja) 2012-08-15
SI1781657T1 (sl) 2013-07-31
US20130150383A1 (en) 2013-06-13
HRP20130406T1 (hr) 2013-06-30
MA28357A1 (fr) 2006-12-01
AR047669A1 (es) 2006-02-01
US20100010021A1 (en) 2010-01-14
EP1781657A2 (en) 2007-05-09
EP1781657B1 (en) 2013-03-27
US20150080418A1 (en) 2015-03-19
KR101100601B1 (ko) 2011-12-29

Similar Documents

Publication Publication Date Title
BRPI0507604A (pt) medicamentos com atividade de receptor hm74a
BR0308196A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto
BRPI0517458A (pt) derivados da xantina com atividade para o receptor hm74a
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BR0210838A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BR0214825A (pt) Uréias de 2-aminobenzotiazóis como moduladores de adenosina
CN104230971A (zh) 作为脂肪酰胺水解酶抑制剂的硼酸和酯
BRPI0409109A (pt) novos compostos
SE0104340D0 (sv) New compounds
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0512330A (pt) derivados de pirazol-pirimidina
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR0206935A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
DOP2002000512A (es) Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE LLC (US)

Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements